Navigation Links
NCCN Updates Esophageal and Gastric Cancer Guidelines

JENKINTOWN, Pa.--(BUSINESS WIRE)--May 22, 2007 - The National Comprehensive Cancer Network (NCCN) announces updates to two NCCN Clinical Practice Guidelines in Oncology(TM) -- Esophageal Cancer and Gastric Cancer. The NCCN Guidelines are updated continuously by panels of world-renowned experts and are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings.

In response to favorable Phase III trials (ML 17032 and REAL 2), the panel added oral fluoropyrimidine, Capecitabine (Xeloda(R), Roche) as an option for treatment of esophageal and gastric cancer. The REAL 2 study, the largest ever phase III study in advanced esophageal and gastric cancer, found that Capecitabine may replace 5-FU and Oxaliplatin may replace Cisplatin in triplet regimens used for the treatment of advanced esophageal and gastric cancer.

A new page entitled "Principles of Surgery" was added to outline recommended NCCN Guidelines for esophageal surgery. A similar "Principles of Surgery" page was added to the NCCN Gastric Cancer Guidelines.

Based on positive results from the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial, the ECF regimen (epirubicin/cisplatin/5-FU) has been added for pre- and post-operative chemotherapy for surgically treatable and potentially curable gastric cancers. The MAGIC trial showed that patients with gastric cancer had a better 5-year survival rate, decreased tumor size and significantly improved progression-free and overall survival when ECF was used perioperatively.

The NCCN Clinical Practice Guidelines in Oncology(TM) are available free of charge at www.nccn.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the qualit y and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

For more information, visit www.nccn.org.

Contact

NCCN
Thomas Mitchell, 215-690-0245
mitchell@nccn.org
www.nccn.org


'"/>




Related medicine technology :

1. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
5. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
6. New Advances in Gastric Diagnostics: Smaller is Better
7. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Wound care devices and products ... the wound. The industry mainly consists of establishments engaged ... treatment of wounds caused by mechanical, chemical, thermal, and ... such as diabetes, skin related diseases, immunological diseases, and ... was the largest region in the wound care ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... report to their offering. ... The global gas chromatograph market to grow at ... The report, Global Gas Chromatograph Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/29/2017)... DIEGO , March 29, 2017 Avelas Biosciences, Inc., ... from diagnosis through treatment, today announced that Carmine N. Stengone ... the company at the Needham & Company 16 th Annual ... (8:20 a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of Turmeric. ... for thousands of years. , "The West has caught on, and has discovered Turmeric, ... Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " The ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):